Evaluation of Hereditary Cancer Educational Videos

N/AActive Not RecruitingNCT06157801

M.D. Anderson Cancer Center43 enrolled

Overview

To learn if educational videos can help participants be more informed about hereditary cancers (ones that run in the family).

Primary Objective Determine the impact of educational videos on: * Participant's hereditary cancer knowledge. * Participant's confidence to share hereditary cancer information with family members. Secondary Objective * Determine impact of educational videos on participant's confidence to undergo hereditary cancer screening. * Identify opportunities to tailor and improve the educational video's content, style, and understandability per participant preferences and feedback.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hereditary Cancer

Interventions

Interview StudyBEHAVIORAL

All study participants will have the following demographic information collected from their medical records: * Sex (Male/Female/Other) * Date of birth * Preferred language (English/Spanish) * Health insurance status (for example: private insurance, HCHD "gold card") * Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis) * Genetic testing result (gene with pathogenic/likely pathogenic variant) * Date of genetic testing result * Date of documented result disclosure.

Survey StudyBEHAVIORAL

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Participants of The Harris Health System Lyndon B. Johnson (LBJ) Hospital outpatient oncology clinics (i.e., Gynecologic Oncology, Medical Oncology). 2. 18 years of age or older. 3. Speaks and/or reads English or Spanish. 4. Has a pathogenic or likely pathogenic variant (mutation) in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM on germline genetic testing. 5. Has a documented genetic testing results disclosure encounter (i.e. telephone call, follow-up appointment). Exclusion Criteria: 1. No longer receives outpatient care at LBJ Hospital at time of recruitment. 2. Has only a variant of uncertain significance in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM. 3. Has only a pathogenic or likely pathogenic variant in gene other than BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, or EPCAM. 4. Is unwilling, unable, or requires a legally authorized representative to provide informed consent.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Outcomes

Primary Outcomes

Hereditary Cancer Multidimensional Measure of Informed Choice Questionnaires

Hereditary Cancer Multidimensional Measure of Informed Choice (MMIC) Knowledge Score scale: (1-8) true or false

Time frame: through study completion; an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.